Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of TAK-536 Pediatric Granules vs Tablets
NCT03042299Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2017
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of azilsartan in hypertension (HTN) (2 arms), sponsored by Takeda. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to 48 Hours Postdose and Maximum Observed Plasma Concentration. Started Feb 2017; status: completed.
02
Drugs
azilsartan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03042299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03042299.